Vice President, Consulting, Certara
Dr. Felix Boakye-Agyeman is Vice President of Pharmacometrics within the Integrated Drug Development (IDD) group at Certara, a global leader in model-informed drug development. Certara partners with more than 2,300 organizations worldwide and has contributed over 99% of all new drug approvals in the past decade.
At Certara, Dr. Boakye-Agyeman leads a multidisciplinary team of scientists who integrate quantitative modeling and clinical pharmacology, and to optimize drug development across therapeutic areas. His work has directly supported the development and approval of multiple therapies, particularly in oncology, immunology, and pediatric indications.
With a background spanning medicine, clinical pharmacology, and quantitative sciences, Dr. Boakye-Agyeman is recognized for advancing model-informed strategies for special and vulnerable populations, ensuring that data-driven innovation translates into safer and more effective therapies.
Prior to joining Certara, he held leadership roles at Synteract, where he oversaw pharmacometric consulting for adult and pediatric programs, and at the Duke Clinical Research Institute (DCRI), supporting early-phase and pediatric trials through the NIH-funded Pediatric Trials Network. His contributions have informed pediatric dosing strategies and labeling updates by major regulatory agencies, including the FDA, EMA, PMDA, NMPA, and Health Canada.
Beyond his role at Certara, Dr. Boakye-Agyeman serves on the Board of Africa Partners Medical (APM), where for over 15 years he has contributed to health system strengthening, medical training, and quality improvement initiatives across Ghana and West Africa.
Functional Expertise
- 群体 PK
- Exposure Response Analysis
- PK/PD 分析
- Non-compartmental analysis
- Concentration QTc analysis
- 临床药理学
实践领域
- 肿瘤学
- Autoimmune
- Infectious diseases
- Antibody drug conjugates (ADC)
- Special Populations (Pediatrics, Maternal Health)
Sr. Director, Pharmacometrics
Huub is a senior pharmacometrician with an in-depth knowledge of pharma R&D, with 20+ years of pharmaceutical industry / consulting experience. He has a broad regulatory experience reflected by contributions to multiple new drug applications across therapeutic areas. He has proficient modeling skills in population PK, PKPD and exposure-response analysis. Huub has demonstrated ability to successfully lead pharmacometric project teams covering the full chain from scoping, pricing, setting up M&S analysis plans, execution of analysis and authoring regulatory quality reports.
Functional Expertise
- 临床药理学
- DMPK
- 药物开发战略
- Non-compartmental analysis
- PK/PD 分析
- 群体 PK
实践领域
- Antibody drug conjugates (ADC)
- 中枢神经系统（CNS）
- 肿瘤学
- Orphan diseases
- 儿科
- Psychiatric
VP, Clinical Pharmacology Consulting
Dr Nolan Wood joined Certara in 2017 as a consultant in the clinical pharmacology and translational medicine group, providing clinical pharmacology leadership and stewardship to develop high quality, innovative clinical pharmacology programs supporting global drug development. Dr. Wood has more than 35 years of global drug development experience working in the pharmaceutical industry and as a consultant, covering all stages of development, from first-in-human studies through to regulatory submissions, including pediatric drug development. He has worked across a wide range of therapeutic areas involving both small molecules and biological products. Working as the global clinical pharmacology lead, he has taken responsibility for implementing model-informed drug development strategies resulting in successful global regulatory approvals for several compounds. He has contributed to the design and execution of studies in special populations including patients with renal and hepatic impairment and pediatric populations. Dr. Wood has extensive experience of interactions with the major health authorities and has written Clinical Pharmacology sections for regulatory submissions and requests for information.
Following a degree in Pharmacology, Dr Wood obtained a PhD in the Clinical Pharmacology Group at the University of Southampton. He has (co-) authored over 40 peer-reviewed publications and is a member of the British Pharmacological Society.
Functional Expertise
- 临床药理学
- 药物开发战略
- Drug product development
- 尽职调查
- PK/PD 分析
- 模型引导的药物开发
实践领域
- 免疫学
- 免疫肿瘤学
- Infectious diseases
- 肿瘤学
- 儿科
- Respiratory
Senior Vice President, Global Quantitative Sciences Services, Certara Drug Development Solutions
Rik de Greef 是 Certara 公司全球定量科学服务的高级副总裁。Rik 曾在荷兰莱顿大学接受 PK-PD 科学家培训。多年来，Rik 在 Organon 及其后继公司 Schering-Plough 和 Merck/MSD 担任了重要职务。最近，他担任临床 PK-PD 的负责人。在担任该职务期间，他领导小组从 15 名同事扩展到 34 名同事。此外，他还领导了 Merck 公司肿瘤学关键项目 — pembrolizumab 的 BLA 申请早期临床部分的准备工作。
